Related Experiment Video

Updated: Mar 9, 2026

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K

[Targeted suppression of miRNA-21 inhibit K562 cells growth through PTEN-PI3K/AKT signaling pathway]

M H Liu1, L Yang, X J Liu

  • 1Department of Hematology, The Second Affiliated Hospital, Hebei Midical University, Shijiazhuang 050000, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|December 21, 2016
PubMed

Insights

Inhibiting microRNA-21 (miRNA-21) in leukemia K562 cells suppressed the PTEN-PI3K/AKT pathway, reducing cell proliferation and increasing apoptosis. This suggests miRNA-21 inhibition is a potential therapeutic strategy for leukemia.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Leukemia K562 cells exhibit dysregulated PTEN-PI3K/AKT signaling.
  • MicroRNA-21 (miRNA-21) is implicated in the pathogenesis of various cancers, including leukemia.
  • Understanding miRNA-21's role in K562 cells is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the biological function of K562 cells by inhibiting miRNA-21 expression.
  • To elucidate the molecular changes in the PTEN-PI3K/AKT signaling pathway in leukemia K562 cells.
  • To explore the potential of targeting miRNA-21 for leukemia treatment.

Main Methods:

  • K562 cells were transfected with a synthetic miRNA-21 inhibitor via electrotransfection.
  • Quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to assess miRNA-21 expression levels.
  • Cell proliferation and apoptosis were evaluated using MTT assays and flow cytometry, respectively.
  • Western blotting was employed to analyze the protein expression of PTEN, PI3K, and p-AKT.

Main Results:

  • Inhibition of miRNA-21 significantly reduced its expression in K562 cells.
  • A marked increase in K562 cell apoptosis and a significant decrease in cell proliferation were observed.
  • Western blot analysis revealed upregulation of PTEN and downregulation of PI3K and p-AKT protein expression.
  • These molecular changes indicate suppression of the PTEN-PI3K/AKT signaling pathway.

Conclusions:

  • Inhibiting miRNA-21 expression in K562 cells effectively suppresses the PTEN-PI3K/AKT pathway.
  • Upregulation of PTEN and downregulation of PI3K/p-AKT contribute to the observed anti-proliferative and pro-apoptotic effects.
  • Targeting miRNA-21 presents a promising therapeutic strategy for leukemia by modulating key signaling pathways.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K